Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1658358 | 0.97 | LMNA (0.41) | SMN1; SMN2LMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL1658329 | 0.97 | LMNA (0.41) | SMN1; SMN2LMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL19501042 | 0.91 | — | — | |
| SCHEMBL16786319 | 0.91 | — | — | |
| SCHEMBL26118 | 0.91 | — | — | |
| SCHEMBL6003917 | 0.82 | SMN1; SMN2 (0.38) | SMN1; SMN2LMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL5907081 | 0.80 | SMN1; SMN2 (0.36) | SMN1; SMN2LMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL25277182 | 0.78 | LMNA (0.39) | SMN1; SMN2LMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL1658244 | 0.78 | SMN1; SMN2 (0.48) | SMN1; SMN2LMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL9455987 | 0.78 | SMN1; SMN2 (0.35) | SMN1; SMN2LMNAALDH1A1TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2377844-B1 | Cyclohexane polycarboxylic acid derivatives containing adjuvants | BASF SE (DE) | 2017-10-18 | — | — | EP | claimed |
| EP-3094613-A1 | PROCESSES FOR THE SYNTHESIS OF CHIRAL 1-ALKANOLS | Purdue Research Foundation, Inc. (US) | 2016-11-23 | — | — | EP | claimed |
| WO-2015106045-A1 | PROCESSES FOR THE SYNTHESIS OF CHIRAL 1-ALKANOLS | PURDUE RESEARCH FOUNDATION (US) | 2015-07-16 | — | — | WO | claimed |
| EP-2377844-A2 | Cyclohexane polycarboxylic acid derivatives containing adjuvants | BASF SE (DE) | 2011-10-19 | — | — | EP | claimed |
| US-7816553-B2 | Cyclohexane polycarboxylic acid derivatives containing adjuvants | BASF SE (DE) | 2010-10-19 | — | — | US | claimed |
| EP-4638409-A1 | PLASTICIZER COMPOUND | BASF SE (DE) | 2025-10-29 | — | — | EP | disclosed |
| US-12428364-B2 | Method for processing benzene polycarboxylic acid esters and use of same to produce cyclohexane polycarboxylic acid esters | BASF SE (DE) | 2025-09-30 | — | — | US | disclosed |
| EP-3356459-B2 | PLASTICIZER COMPOSITION CONTAINING POLYMERIC DICARBOXYLIC ACID ESTERS AND DICARBOXYLIC ACID DIESTERS | BASF SE (DE) | 2025-09-17 | — | — | EP | disclosed |
| EP-4596616-A2 | PLASTICIZER COMPOSITION CONTAINING POLYMERIC DICARBOXYLIC ACID ESTERS AND DICARBOXYLIC ACID DIESTERS | BASF SE (DE) | 2025-08-06 | — | — | EP | disclosed |
| WO-2024256670-A1 | PLASTICIZER COMPOSITION | BASF SE (DE) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024153687-A1 | METHOD FOR PRODUCING 1,2-CYCLOHEXANE DICARBOXYLIC ACID DIALKYL ESTERS | BASF SE (DE) | 2024-07-25 | — | — | WO | disclosed |
| WO-2024133358-A1 | PLASTICIZER COMPOUND | BASF SE (DE) | 2024-06-27 | — | — | WO | disclosed |
| WO-2009095126-A1 | MIXTURES OF DIISONONYL ESTERS OF TEREPHTHALIC ACID, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF | EVONIK OXENO GMBH (DE) | 2009-08-06 | — | — | WO | disclosed |
| EP-2049254-A2 | PROCESS FOR REGENERATING RUTHENIUM CATALYSTS FOR THE RING HYDROGENATION OF PHTHALATES | BASF SE (DE) | 2009-04-22 | — | — | EP | disclosed |
| US-20080039646-A1 | Cyclohexane Polycarboxylic Acid Derivatives Containing Adjuvants | BASF AKTIENGESELLSCHAFT (DE) | 2008-02-14 | — | — | US | disclosed |
| WO-2008015135-A2 | PROCESS FOR REGENERATING RUTHENIUM CATALYSTS FOR THE RING HYDROGENATION OF PHTHALATES | BASF SE (DE) | 2008-02-07 | — | — | WO | disclosed |
| EP-1761596-A2 | CYCLOHEXANE POLYCARBOXYLIC ACID DERIVATIVES CONTAINING ADJUVANTS | BASF AKTIENGESELLSCHAFT (DE) | 2007-03-14 | — | — | EP | disclosed |
| US-20070003583-A1 | Cosmetic compositions comprising cyclohexanepolycarboxylic acid derivatives | BASF AKTIENGESELLSCHAFT (DE) | 2007-01-04 | — | — | US | disclosed |
| WO-2005123821-A2 | CYCLOHEXANE POLYCARBOXYLIC ACID DERIVATIVES CONTAINING ADJUVANTS | BASF AKTIENGESELLSCHAFT (DE) | 2005-12-29 | — | — | WO | disclosed |
| WO-2004098547-A1 | COSMETIC COMPOSITIONS COMPRISING CYCLOHEXANEPOLYCARBOXYLIC ACID DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070003583-A1 | Cosmetic compositions comprising cyclohexanepolycarboxylic acid derivatives | PHGDH, CUTA, PCCA | SMN1; SMN2 4725/4885LMNA 1901/4885ALDH1A1 510/4885 |
| US-20080039646-A1 | Cyclohexane Polycarboxylic Acid Derivatives Containing Adjuvants | PCNA, CCNA1, CCNA2 | SMN1; SMN2 4866/4885LMNA 3270/4885ALDH1A1 3278/4885 |
| US-12428364-B2 | Method for processing benzene polycarboxylic acid esters and use of same to produce cyclohexane polycarboxylic acid esters | DDT, HPD, DDC | SMN1; SMN2 3913/4885LMNA 3771/4885ALDH1A1 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.